Medical person with blue gloves handling vials.

We would all be excused for wanting 2020 to disappear in a fog of medical marijuana. In case you missed it, here’s a recap of a very busy year for Ogletree Deakins Drug Testing Practice Group.

As we predicted in 2019, most of this year’s action concerned medical and recreational marijuana. Not to be missed, however, there were important developments regarding accommodation of opiate addiction, pandemic-related drug testing guidance by the U.S. Department of Transportation (DOT), and even decriminalization of narcotics and psychedelic drugs. Here is a rundown of the highlights from 2020.

If the growth of the International Cannabis Bar Association is an accurate predictor, medical and recreational marijuana accommodation will continue to be a hot area in 2021. But if 2020 is any indicator, there will be a few surprises along the way too. Follow Ogletree Deakins Drug Testing blog to stay abreast of all developments. Happy New Year!



Browse More Insights

Practice Group

Drug Testing

Ogletree Deakins understands that employers face complex and nuanced issues when implementing and enforcing drug and alcohol testing and substance abuse policies. Drawing on decades of experience advising and defending drug testing laboratories, and public and private employers across the country and internationally, our attorneys provide highly responsive legal service

Learn more

Sign up to receive emails about new developments and upcoming programs.

Sign Up Now